Quizartinib (dihydrochloride)

Quizartinib (dihydrochloride)

• CAS Number: 1132827-21-4
• UNSPSC Description: Quizartinib dihydrochloride (AC220 dihydrochloride) is the dihydrochloride salt form of Quizartinib (HY-13001). Quizartinib dihydrochloride is an orally active, highly selective and potent second-generation type II FLT3 tyrosine kinase inhibitor, with a Kd of 1.6 nM. Quizartinib dihydrochloride inhibits wild-type FLT3 and FLT3-ITD autophosphorylation in MV4-11 cells with IC50s of 4.2 and 1.1 nM, respectively. Quizartinib dihydrochloride can be linked to the VHL ligand via an optimized linker to form a PROTAC FLT3 degrader. Quizartinib dihydrochloride induces apoptosis[1][2][3].
• Target Antigen: Apoptosis; FLT3; Ligands for Target Protein for PROTAC
• Type: Reference compound
• Related Pathways: Apoptosis;PROTAC;Protein Tyrosine Kinase/RTK
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/quizartinib-dihydrochloride.html
• Solubility: DMSO : 33.33 mg/mL (ultrasonic;adjust pH to 12 with 1 M NaOH)
• Smiles: O=C(NC1=CC=C(C2=CN3C(SC4=CC(OCCN5CCOCC5)=CC=C34)=N2)C=C1)NC6=NOC(C(C)(C)C)=C6.[H]Cl.[H]Cl
• Molecular Weight: 633.59
• References & Citations: [1]Zarrinkar PP, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood, 2009, 114(14), 2984-2992.|[2]Puissant A, et al. SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell. 2014 Feb 10;25(2):226-42.|[3]Sun X, et al. PROTACs: great opportunities for academia and industry. Signal Transduct Target Ther. 2019 Dec 24;4:64.
• Shipping Conditions: Room Temperature
• Clinical Information: Launched